NCT04968002Unknown2 期
Application of Pablizumab Combined With Apatinib and Chemotherapy in Resectable Non-small Cell Lung Cancer： A Prospective, Single Arm, Single Center Phase II Clinical Study of Neoadjuvant Therapy
Second Affiliated Hospital, School of Medicine, Zhejiang University1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2021年8月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- The main pathological response rate
研究概览
简要总结
This is a prospective, single arm, single center clinical study to determine the efficacy and safety of pablizumab combined with apatinib and neoadjuvant chemotherapy in patients with stage iia-iiia non-small cell lung cancer. No EGFR mutation or ALK gene translocation was found in the untreated patients with NSCLC stage IIa-IIIb diagnosed by imaging, histopathology or cytology. After informed consent is signed by the patients. The patients were treated according to the protocols. The patients were followed up from adjuvant treatment and follow-up to relapse free survival until disease progression, withdrawal of informed consent, loss of follow-up or death.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age: 18-75 years old, male or female;
- •Non small cell lung cancer was diagnosed by imaging, histopathology or cytology
- •The resectable clinical stage assessed by the investigators was stage IIA - IIIA (according to AJCC)
- •TNM staging, 8th Edition);
- •ECoG PS score: 0-1;
- •According to the RECIST version 1.1 evaluation standard, at least one image can be measured
- •The lesions were measured;
- •There was no operation contraindication in preoperative organ function examination;
- •The laboratory examination indexes meet the requirements:
- •No previous treatment for NSCLC, including surgery and chemotherapy
- •Therapy, radiotherapy, targeted therapy, hormone or immunotherapy, etc;
- •Women of childbearing age agreed to use contraception during the study and within 6 months after the end of the study; study
- •The serum or urine pregnancy test was negative in the first seven days, and the patients were not in lactation
- •The subjects can understand the research situation and sign the informed consent voluntarily.
排除标准
- •Have received any treatment including chemotherapy in the past
- •Or radiotherapy;
- •The tumor has invaded important blood vessels or the tumor is in the treatment stage according to the judgment of the researcher
- •There is a high possibility of invading important blood vessels and causing massive hemorrhage;
- •Known EGFR mutation or ALK gene translocation;
- •There are locally advanced unresectable diseases and metastatic diseases;
- •She had been suffering from the need to use corticosteroids (prednisolone) in 14 days before randomization
- •Daily dose of nisone or equivalent (10 mg) or other immunosuppressive drugs
- •Any disease requiring systemic treatment. Local replacement steroids are permitted
- •(daily dose ≤ 10 mg of prednisone or equivalent) and prescription corticosteroids
- •Short term (≤ 7 days) prophylactic use of alcohol or for the treatment of non autoimmune.
- •Any active autoimmune disease or history of autoimmunity;
- •Active autoimmune diseases or autoimmune diseases that may recur
- •History. Admission of well controlled type I diabetes and hormone replacement therapy are allowed.
- •Hypothyroidism, well controlled celiac disease, and no need for complete treatment
- •Skin diseases (such as vitiligo, psoriasis or alopecia) treated by the body or not
- •Due to the absence of recurrence of the disease is not expected.
- •Interstitial lung disease, non infectious pneumonia or poorly controlled diseases (including pulmonary fibrosis)
- •History of vitamin C, acute lung disease, etc.
- •active hepatitis B (defined as screening hepatitis B virus surface antigen [HBsAg])
- •The results were positive and HBV-DNA was detected. The detection value was higher than that in the study
- •Upper limit of normal value of cardiology laboratory) or hepatitis C (defined as screening hepatitis C virus table)
- •The subjects with positive results of hcsab and HCV-RNA;
- •Known human immunodeficiency virus (HIV) infection (known HIV antibody positive);
- •Inoculate live vaccine within 30 days before the first administration. Including but not limited to the following:
- •Mumps, rubella, measles, varicella / herpes zoster (varicella), yellow fever
- •Rabies, BCG and typhoid vaccine (inactivated virus vaccine allowed);
- •Suffering from uncontrolled clinical symptoms or diseases of the heart;
- •Long term antiplatelet therapy is needed;
- •Those who are allergic to any drug in this program;
- •Pregnant or lactating women;
- •According to the judgment of the researcher, the subjects may confuse the test results and interfere
- •It is not in the best interests of the subjects to participate in the whole trial
- •A history or current evidence of any disease, treatment, or laboratory abnormality
- •It's a good idea.
- •Active bleeding.
- •Exclusion criterion:
- •Ever received any treatment including chemotherapy or radiotherapy in the past;
- •The tumor has invaded important blood vessels. There is a high possibility of invading important blood vessels and causing massive hemorrhage if the tumor is in the treatment stage process according to the judgment of the researcher;
- •EGFR mutation or ALK gene translocation;
- •There are locally advanced unresectable diseases and metastatic diseases;
- •Patients had been suffering from the need to use corticosteroids (prednisolone) in 14 days before randomization grouping. Daily dose of nisone or equivalent (10 mg) or other immunosuppressive drugs. Any active autoimmune disease or history of autoimmunity;
- •Active autoimmune diseases or autoimmune diseases that may recur
- •Interstitial lung disease, non infectious pneumonia or poorly controlled diseases (including pulmonary fibrosis) etc.
- •active hepatitis B (defined as screening hepatitis B virus surface antigen [HBsAg]). And the results were positive and HBV-DNA was detected. The detection value was higher than that in the study upper limit of normal value of cardiology laboratory) or hepatitis C (defined as screening hepatitis C virus table and the subjects with positive results of hcsab and HCV-RNA;
- •Known human immunodeficiency virus (HIV) infection (known HIV antibody positive);
- •Inoculated live vaccine within 30 days before the first administration. Including but not limited to the following: Mumps, rubella, measles, varicella / herpes zoster (varicella), yellow fever Rabies, BCG and typhoid vaccine (inactivated virus vaccine allowed);
- •Suffering from uncontrolled clinical symptoms or diseases of the heart;
- •Long term antiplatelet therapy is needed;
- •Those who are allergic to any drug in this program;
- 另有 3 项未显示
研究组 & 干预措施
Preoperative neoadjuvant therapy for patients with stage IIa-IIIa non-small cell lung cancer.
Experimental
No EGFR mutation or ALK gene translocation was found in the untreated patients with NSCLC stage IIa-IIIb diagnosed by imaging, histopathology or cytology. After informed consent is signed by the patients. The patients were treated according to the protocols.
干预措施: pablizumab combined with apatinib and neoadjuvant chemotherapy (Drug)
结局指标
主要结局
The main pathological response rate
时间窗: through surgical treatment completion, an average of 4 months
After neoadjuvant therapy, the residual tumor was observed under microscope with a result of the proportion of tumor cells was less than or equal to 10%.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
不适用
PABLIXIMAB as Neoadjuvant Therapy for Head and Neck Squamous-cell CarcinomaSquamous Cell Carcinoma of Head and NeckNeoadjuvant TherapyImmunotherapyNCT06125223Xijing Hospital45
Unknown
1 期
Apatinib Combined With S-1 for the Treatment of Recurrent/Metastatic Head and Neck MalignanciesHead and Neck CancerNCT03654612China International Medical Foundation30
招募中
2 期
Apatinib Combined with Temozolomide and Etoposide Capsules in the Treatment of Recurrent Medulloblastoma in ChildrenRecurrent MedulloblastomaNCT04501718Beijing Sanbo Brain Hospital44
已完成
2 期
First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GCAdvanced Gastric AdenocarcinomaNCT06238752Renmin Hospital of Wuhan University33
Unknown
1 期
Apatinib Combined With Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast CancerAdvanced Triple Negative Breast CancerNCT05019690Fujian Cancer Hospital20